Cognetivity Neurosciences Ltd (1UB.MU)
Chart Events
Performance Outlook
| Previous Close | 0.1885 |
| Open | 0.1815 |
| Bid | 0.1645 x N/A |
| Ask | 0.1880 x N/A |
| Day's Range | 0.1815 - 0.1815 |
| 52 Week Range | 0.1375 - 0.3860 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Dec 16, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 1UB.MU
Related Research
- Newsfile
Cognetivity Neurosciences' CognICA Platform Successfully Monitors Cognitive Performance in Alzheimer's Patients Receiving Disease-Modifying Therapy
Demonstrable sensitivity and clinical usability of Cognetivity's screening and monitoring tool leaves the company well placed to support the dawning era of targeted therapies for neurodegenerative disease Vancouver, British Columbia--(Newsfile Corp. - January 24, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer env
- Newsfile
Cognetivity Neurosciences Provides Update on 2022 Corporate Achievements
Key achievements in 2022 included continued collaboration with global pharmaceutical firms working in neurodegenerative disease, new and ongoing commercial deployments spanning three continents, and completion of a fundraising round worth CAD 4.5 million Vancouver, British Columbia--(Newsfile Corp. - January 10, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platfo
- Newsfile
Cognetivity Neurosciences' Brain Health Platform Cited as Case Study as Part of Early Dementia Detection Policy Recommendations by Alzheimer's Research UK
Policy paper published by UK's leading dementia research charity emphasizes importance of early detection in dementia diagnosis, citing Cognetivity's CognICA(TM) as an innovative solution for use in primary care Vancouver, British Columbia--(Newsfile Corp. - December 13, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and cons
